Literature DB >> 10516339

Increased serum and urinary neopterin in nephrotic syndrome indicate cell-mediated immune dysfunction.

K Oda1, T Arai, M Nagase.   

Abstract

T-cell-mediated immune disturbances are likely but not certain to cause the nephrotic syndrome. Because neopterin (NP) production is closely related to activation of cell-mediated immunity, we addressed the question by measuring serum NP concentrations and urinary NP/creatinine (Cr) ratios, as well as by assessing interstitial lymphocyte and monocyte infiltration in the kidney and activation of the same cell types in peripheral blood. Finally, we observed whether urinary NP/Cr ratios in nephrotic syndrome are changed by steroid therapy. Seventy-four patients with primary glomerulonephritis were divided into 4 groups based on presence or absence of nephrotic syndrome and presence or absence of mesangial proliferation and expansion. Serum and urinary NP concentrations were measured chromatographically. Infiltrating cells in the kidney were identified by immunohistochemistry, and activation of peripheral blood cells was examined by fluorescent surface marker antibodies and flow cytometry. Irrespective of the pathohistology of glomeruli, nephrotic groups showed significantly higher urinary NP/Cr ratios and serum NP concentrations. Nephrotic groups also exhibited more activation of T cells in peripheral blood than did nonnephrotic groups or a healthy control group. Serum NP did not correlate with extent of interstitial renal infiltrates. Steroid therapy decreased urinary NP/Cr ratios in steroid-responsive patients, but not in steroid-resistant patients. Increased serum NP concentrations and urinary NP/Cr ratios may reflect disordered cell-mediated immunity in the nephrotic syndrome, irrespective of glomerular histology or interstitial cell infiltration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516339     DOI: 10.1016/S0272-6386(99)70383-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Urinary neopterin: an immune activation marker in mesangial proliferative glomerulonephritis.

Authors:  Kazuyuki Ueno; Masaki Shimizu; Tadafumi Yokoyama; Sayaka Ishikawa; Yuko Tasaki; Natsumi Inoue; Naotoshi Sugimoto; Kazuhide Ohta; Akihiro Yachie
Journal:  Clin Exp Nephrol       Date:  2014-05-25       Impact factor: 2.801

2.  Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients.

Authors:  Yesim Ozkan; Guray Mete; Aylin Sepici-Dincel; Vesile Sepici; Bolkan Simsek
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

3.  The clinical significance of serum and urinary neopterin levels in several renal diseases.

Authors:  Hyun Young Lhee; Hyang Kim; Kwan Joong Joo; Soo Suk Jung; Kyu Beck Lee
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

4.  Evaluation of plasma levels of neopterin and soluble CD40 ligand in patients with acute ischemic stroke in upper Egypt: can they surrogate the severity and functional outcome?

Authors:  Abeer A Tony; Effat Ae Tony; Wafaa Salah Mohammed; Emad F Kholef
Journal:  Neuropsychiatr Dis Treat       Date:  2019-02-22       Impact factor: 2.570

5.  Vascular Endothelial Growth Factor (VEGF) and Neopterin Levels in Children with Steroid-sensitive and Steroid-resistant Nephrotic Syndrome.

Authors:  Riska Habriel Ruslie; Darmadi Darmadi; Gontar Alamsyah Siregar
Journal:  Med Arch       Date:  2021-04

6.  Association between serum neopterin and inflammatory activation in chronic kidney disease.

Authors:  Ashok Kumar Yadav; Vinod Sharma; Vivekanand Jha
Journal:  Mediators Inflamm       Date:  2012-08-26       Impact factor: 4.711

7.  Relationship Between Leptin and Neopterin Levels and Disease Activation Parameters in Patients With Rheumatoid Arthritis.

Authors:  Arif Gülkesen; Gürkan Akgöl; Türkan Tuncer; Gül Ayden Kal; Selda Telo; Ahmet Kürşad Poyraz; Arzu Kaya
Journal:  Arch Rheumatol       Date:  2016-04-14       Impact factor: 1.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.